Journal Mobile Options
Table of Contents
Vol. 136, No. 1, 2005
Issue release date: January 2005
Int Arch Allergy Immunol 2005;136:58–72

A New Combined Test with Flowcytometric Basophil Activation and Determination of Sulfidoleukotrienes Is Useful for in vitro Diagnosis of Hypersensitivity to Aspirin and other Nonsteroidal Anti-Inflammatory Drugs

Sanz M.L. · Gamboa P. · de Weck A.L.
aDepartment of Allergology and Clinical Immunology, University of Navarra, Pamplona, and bAllergy Unit, Hospital Basurto, Bilbao, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: We assessed whether nonsteroidal anti-inflammatory drugs (NSAIDs) may provoke blood basophil activation in vitro in aspirin- and NSAID-hypersensitive patients, as detected by a flowcytometric technique using the CD63 marker – flowcytometric basophil activation test (FAST) assay – in addition to the sulfidoleukotriene (sLT) release – the cellular allergen stimulation test (CAST). Methods: Sixty aspirin- and/or NSAID-hypersensitive patients were studied. Thirty control patients without history and negative provocation challenge were also included. The percentage of activated basophils after in vitro stimulation with NSAIDs at 3 different concentrations was evaluated by an anti-CD63 phycoerythrin conjugate (FAST assay) and the amount of sLTs released in the cell supernatant by ELISA (CAST assay). Results: For aspirin, the FAST indicated a sensitivity of 41.7%, a specificity of 100%, a positive predictive value of 100% and a negative predictive value of 99.4%; for paracetamol 11.7 and 100%, for metamizol 15 and 100%, for diclofenac 43.3 and 93.3%, and for naproxen 54.8 and 74.1%. Many patients showed positive tests to more than 1 NSAID. When considering the first 4 NSAIDs, the global sensitivity increased to 66.7%, while the specificity remained at 93.3%. The addition of the CAST results still increased the sensitivity up to 73.3%, but with a decrease of the specificity to 71.4%. Conclusions: The FAST shows a high percentage of positive reactions, which may reach 60–70% when 4 NSAIDs are tested and even 88% when the test is performed within 1 month of the last clinical drug exposure and reaction. The test has a high specificity above 90%. The addition of sLT determinations yields additional information in a few isolated cases. It is suggested that this test, when properly used, may help avoid some cumbersome and dangerous provocation challenges.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Szczeklik A, Stevenson D: Aspirin-induced asthma: Advances in pathogenesis, diagnosis and management. J Allergy Clin Immunol 2003;111:913–921.
  2. Szczeklik A, Stevenson DD: Aspirin-induced asthma: Advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5–13.
  3. Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhard J, Gladysz U, Malolepszy J, Szczeklik A: Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003;58:1064–1066.
  4. Faich GA: Adverse drug reaction monitoring. N Engl J Med 1986;314:1589–1592.
  5. Sainte-Laudy J: Nine cases of suspected IgE-mediated anaphylaxis induced by aspirin. ACI Int 2002;14:220–222.
  6. Blanca M, Perez E, Garcia JJ, et al: Angioedema and IgE antibodies to aspirin: A case report. Ann Allergy 1989;62:295–298.
  7. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G: Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;1:67–69.
  8. Szczeklik A: The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588–593.
  9. Stevenson DD, Lewis RA: Proposed mechanism of aspirin sensitivity reactions. J Allergy Clin Immunol 1977;80:788–790.
  10. Szczeklik A, Sanak M: Molecular mechanisms in aspirin-induced asthma. ACI Int 2000;12:171–178.
  11. Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, Cohn J, White MV, Igarashi Y, Kaliner MA, Drazen JM, Israel E: Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994;94:1046–1056.
  12. Nasser SM, Pfister R, Christie P, Sousa AR, Barker J, Schmitz-Schumann M, Lee TH: Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996;153:90–96.
  13. Bosso JV, Schwartz LB, Stevenson DD: Tryptase and histamine release during aspirin-induced respiratory reactions. J Allergy Clin Immunol 1991;88:830–837.
  14. O’Sullivan S, Dahlen B, Dahlen SE, Kumlin M: Increased urinary excretion of the prostaglandin D2 metabolite 9α,11β-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996;98:421–432.
  15. Mita H, Endoh S, Kudoh M, Kawagishi Y, Kobayashi M, Taniguchi M, Akiyama K: Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001;56:1061–1067.
  16. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A: A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls following the aspirin challenge. J Allergy Clin Immunol 2003;111:743–749.
  17. Nasser SM, Lee TH: Leukotrienes in aspirin-sensitive asthma; in Szczeklik A, Gryglewski RJ, Vane J (eds): Eicosanoids, Aspirin and Asthma. New York, Dekker, 1998, pp 317–336.
  18. Lee TH, Smith CM, Arm JP, Christie PE: Mediator release in aspirin-induced reactions. J Allergy Clin Immunol 1991;88:827–829.
  19. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL: Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988;137:847–854.
  20. Picado C, Ramis I, Rosello J, Prat J, Bulbena O, Plaza V, Montserrat JM, Gelpi E: Release of peptide leukotriene into nasal secretions after local instillations of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992;145:65–69.
  21. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ: Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002;166:301–306.
  22. Mewes T, Riechelmann H, Klimek L: Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps and aspirin intolerance. Allergy 1996;51:506–510.
  23. Celik G, Bavbeck S, Misirligil Z, Melli M: Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E2 on this release from peripheral blood leukocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 2001;31:1615–1622.
  24. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, Lam BK, Penrose JF, Austen KF, Holgate ST, Sampson AP: Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834–846.
  25. Sanak M, Simon HU, Szczeklik A: Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599–1600.
  26. Sanak M, Szczeklik A: Genetics of aspirin induced asthma. Thorax 2000;55(suppl 2):S45-S47.
  27. Torres-Galvan MJ, Ortega N, Sanchez-Garcia F, Blanco C, Carrillo T, Quiralte J: LTC4-synthase A-444C polymorphism: Lack of association with NSAID-induced isolated periorbital angioedema in a Spanish population. Ann Allergy Asthma Immunol 2001;87:506–510.
  28. Van Sambeck R, Stevenson DD, Baldasaro M, Lam BK, Zhao JL, Yoshida S, Yandora C, Dos JM, Penrose JF: 5′ flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000;106:72–76.
  29. Kawagishi Y, Mita H, Taniguchi M, Maruyama M, Oosaki R, Higashi N, Kashii T, Kobayashi M, Akyama K: Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002;109:936–942.
  30. Stevenson DD, Simon RA: Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs; in Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW (eds): Allergy: Principles and Practice. St Louis, Mosby, 1998, pp 1225–1234.
  31. Czech W, Kapp A, Kownatzki E, Schöpf E: Die Bedeutung der in vitro induzierten Histaminfreisetzung aus isolierten Leukozyten für die Diagnostik pseudo-allergischer Reaktionen auf Azetylsalizylsäure. Allergologie 1990;13:201–204.

    External Resources

  32. Lebel B, Messaad B, Kvedariene V, Rongier M, Bousquet J, Demoly P: Cysteinyl-leukotriene release test (CAST) in the diagnosis of immediate drug reactions. Allergy 2001;56:688–692.
  33. De Weck AL, Stadler BH, Urwyler A, Wehner HU, Bühlmann RP: Cellular antigen stimulation test (CAST): A new dimension in allergy diagnosis. Allergy Clin Immunol News 1993;5:9–14.
  34. Sabbah A, Drouet M, Sainte-Laudy J, Lauret MG, Loiry M: Apport de la cytométrie en flux dans le diagnostic allergologique. Allerg Immunol (Paris) 1997;29:15–21.
  35. De Weck AL: Zellulärer Allergen-Stimulierungstest (CAST). Eine Übersicht und kritische Auswertung der klinischen Anwendung in der Allergiediagnose. Allergologie 1997;20:487–502.
  36. Kubota Y, Imayama S, Toshitani A, Miyahara H, Tanahasshi T, Uemura Y, Koga T, Sugawara S, Kurimoto F, Hata K: Sulfidoleukotriene release test (CAST) in hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 1997;114:361–366.
  37. May A, Weber A, Gall H, Kaufmann R, Zollner TM: Means of increasing sensitivity of an in vitro diagnostic test for aspirin intolerance. Clin Exp Allergy 1999;29:1402–1411.
  38. Pierzchalska M, Mastalerz L, Sanak M, Zalula M, Szczeklik A: A moderate and unspecific release of cysteinyl leukotrienes by aspirin from peripheral blood leukocytes precludes its value for aspirin sensitivity testing in asthma. Clin Exp Allergy 2000;30:1785–1791.
  39. Sanz ML, Sánchez G, Gamboa PM, Vila L, Uasuf C, Chazot M, Diéguez I, De Weck AL: Ag-induced basophil activation: CD63 cell expression detected by flow cytometry in allergic patients to Dermatophagoides pteronyssinus and Lolium perenne. Clin Exp Allergy 2001;31:1007–1013.
  40. Kowalski ML, Ptasinska A, Bienkiewicz B, Pawliczak R, DuBuske L: Differential effects of aspirin and misoprostol on 15-hydroxyeicosa-tetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. J Allergy Clin Immunol 2003;112:505–512.
  41. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WH, Buhring HJ, Valenta R, Valent P: Recombinant allergens promote the expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002;110:102–109.
  42. Garcia-Aviles C, Sanchez-Lopez G, Sanz ML, Uasuf C, Dieguez I, Chazot M, De Weck AL: Flow cytometric allergen stimulation test (FAST) in the in vitro diagnosis of food allergy. Allergy 2000;55(suppl 63):128.
  43. Monneret-Vautrin D, Sainte-Laudy J, Kanny G, Frémont S: Human basophil activation measured by CD63 expression and LTC4 release in IgE-mediated food allergy. Ann Allergy Asthma Immunol 1999;82:33–40.
  44. Sainte-Laudy J, Sabbah A, Drouet M, Lauret MG, Loiry M: Diagnosis of venom allergy by flow cytometry. Correlation with cinical history, skin tests, specific IgE, histamine and leukotriene C4 release. Clin Exp Allergy 2000;30:1166–1171.
  45. Binder M, Fierlbeck G, King T, Valent P, Buhring HU: Individual hymenoptera venom compounds induce upregulation of the basophil activation marker ectonucleotide pyrophosphatase/phosphodiesterase (CD203c) in sensitized patients. Int Arch Allergy Immunol 2002;129:160–168.
  46. Sanz ML, Gamboa PM, Garcia-Aviles C, Vila L, Dieguez I, Antepara I, De Weck AL: Flow-cytometric cellular allergen stimulation test in latex allergy. Int Arch Allergy Immunol 2003;130:33–39.
  47. Ebo DG, Lechkar B, Schuerwegh AJ, Bridts CH, De Clerk LS, Stevens WJ: Validation of a two-color flow cytometric assay detecting in vitro basophil activation for the diagnosis of IgE-mediated natural rubber latex allergy. Allergy 2002;57:706–712.
  48. Sanz ML, Gamboa PM, Uasuf C, Vila L, Garcia-Aviles C, Chazot M, De Weck AL: Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002;32:277–286.
  49. Sanz ML, Gamboa PM, De Weck AL: Clinical evaluation of in vitro diagnostic tests in diagnosis of immediate allergic reactions to β-lactam antibiotics. ACI Int 2002;14:185–193.
  50. Abuaf N, Rajoely B, Ghazouani E, Levy DA, Pecquet C, Chabane H, Leynadier F: Validation of flow cytometry assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy. J Allergy Clin Immunol 1999;104:411–418.
  51. Monneret G, Benoit Y, Debard AL, Gutowski MC, Topenot I, Bienvenu J: Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle relaxant drugs. Clin Immunol 2002;102:192–199.
  52. Gamboa PM, Sanz ML, Caballero MR, Antepara I, Urrutia I, Jauregui I, Gonzalez G, Dieguez I, De Weck AL: Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy 2003;58:312–317.
  53. Sanz ML, Maselli JP, Gamboa PM, Garcia-Aviles MC, Oehling A, Diéguez I, De Weck AL: Flow-cytometric basophil activation test. A review. J Investig Allergol Clin Immunol 2002;12:143–154.
  54. De Weck AL, Sanz ML: Flow cytometric cellular allergen stimulation test (FAST/Flow CAST): Technical and clinical evaluation of a new diagnostic test in allergy and pseudo-allergy. ACI Int 2002;14:204–215.
  55. Bush RK, Asbury DW: Aspirin-sensitive asthma; in Busse WW, Holgate ST (eds): Asthma and Rhinitis, ed 2. Oxford, Blackwell, 2000, pp 1315–1325.
  56. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS: Aspirin-sensitive rhinosinusitis/asthma: Spectrum of adverse reactions to aspirin. J Allergy Clin Immunol 1983;71:574–579.
  57. Busse A, Czech W, Schöpf E, Simon JC: Der CAST-ELISA in der Diagnostik von pseudoallergischen Reaktionen gegen Nahrungsmitteladditiva und Azetylsalizylsäure. Allergologie 2000;23:110–115.

    External Resources

  58. Schäfer D, Schmid M, Gode UC, Baenkler BW: Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J 1999;13:638–646.
  59. Hecksteden K, Schäfer D, Stuck BA, Klimek L, Hörmann K: Diagnostik des Analgetika-Intoleranz-Syndroms mittels funktioneller Zelltestung (Analgetika-Intoleranz-Test: AIT). Allergologie 2003;26:263–271.

    External Resources

  60. Gray PA, Warner TD, Vojnovic I, Del Soldato P, Parikh A, Scadding GK, Mitchell JA: Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. Br J Pharmacol 2002;137:1031–1038.
  61. Abrahamsen O, Haas H, Schreiber J, Schlaak M: Differential mediator release from basophils of allergic and non-allergic asthmatic patients after stimulation with anti-IgE and C5a. Clin Exp Allergy 2001;31:368–378.
  62. Goetzl EJ, Valacer DJ, Payan DG, Wong MYS: Abnormal response to aspirin of leukocyte oxygenation of arachidonic acid in adults with aspirin intolerance. J Allergy Clin Immunol 1986;77:693–698.
  63. Szczeklik A: Aspirin-induced asthma as a viral disease. Clin Allergy 1988;18:15–20.
  64. Nakagawa H, Yoshida S, Nakabayashi M, Akahori K, Shoji T, Hasegawa H, Amayasu H: Possible relevance of virus infection for development of analgesic idiosyncrasy. Respiration 2001;68:422–424.
  65. James JM, Kagey-Sobotka A, Sampson HA: Patients with severe atopic dermatitis have activated circulating basophils. J Allergy Clin Immunol 1993;81:1155–1162.
  66. Okuda Y, Hattori H, Takashima T, et al: Basophil histamine release by platelet activating factor in aspirin-sensitive subjects with asthma. J Allergy Clin Immunol 1990;86:548–553.
  67. Czech W, Schöpf E, Kapp A: Release of sulfidoleukotrienes in vitro: Its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid. Inflamm Res 1995;44:291–295.
  68. Wedi B, Kapp A: Aspirin induced adverse skin reactions: New pathophysiological aspects. Thorax 2000;55(suppl 2):S70–S71.
  69. Kikuchi Y, Kaplan AP: A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002;109:114–118.
  70. Okasaki T, Ilea VS, Rosario NA, Reisman RE, Arbesman CE, Lee JR, Middleton E: Regulatory role of prostaglandin E in allergic histamine release with observations on the responsiveness of basophil leukocytes and the effect of acetylsalicylic acid. J Allergy Clin Immunol 1977;60:360–366.
  71. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH: Leukotriene receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493–1499.
  72. Serhan CN, Sheppard KA: Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 1990;85:772–780.
  73. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L, Serhan CN, Szczeklik A: Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000;16:44–49.
  74. Brunner B, Eberlein-König B, Pryzbilla B: Histamine and sulfidoleukotriene release from peripheral blood leukocytes (PBL) of patients with anaphylactoid reactions provoked by acetylsalicylic acid (ASA). J Allergy Clin Immunol 1996;97:344.

    External Resources

  75. Wolanczyk-Medrala A, Malolepszy J, Medrala W, Liebhart J, Linva M, Pietrzak M: CAST-ELISA test in diagnosis of aspirin-idiosyncrasy in aspirin-induced asthma. Allergy 1995;50(suppl 26):246.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50